NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis $0.31 +0.04 (+14.81%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$0.26▼$0.3450-Day Range$0.05▼$0.3452-Week Range$0.05▼$3.10Volume177,007 shsAverage Volume551,461 shsMarket Capitalization$39.29 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vaxxinity alerts: Email Address Ad Golden CrestDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.Click here to receive your complimentary Wealth Management Guide >> About Vaxxinity Stock (NASDAQ:VAXX)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.Read More VAXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Stock News HeadlinesJune 20, 2024 | globenewswire.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineMay 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?July 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.April 22, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 19, 2024 | marketwatch.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | globenewswire.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingJuly 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.March 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 19, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 18, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 3, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceDecember 12, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityNovember 21, 2023 | markets.businessinsider.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 20, 2023 | foxnews.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | msn.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 13, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 8, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+2,158.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-192.58% Return on Assets-88.04% Debt Debt-to-Equity Ratio0.99 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$70,000.00 Price / Sales561.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book2.82Miscellaneous Outstanding Shares126,750,000Free Float45,553,000Market Cap$39.29 million OptionableNot Optionable Beta3.26 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Louis Garfield Reese IV (Age 42)Co-Founder & Executive Chairman of the Board Comp: $275.57kMs. Mei Mei Hu J.D. (Age 41)Co-Founder, President, CEO & Director Comp: $345.14kMs. Sumita Ray J.D. (Age 50)Chief Legal, Compliance & Administrative Officer and Corporate Secretary Comp: $465.56kDr. Jean-Cosme Dodart Ph.D.Chief Scientific OfficerMr. Jon HarrisonChief Government OfficerMr. Mark Joinnides MSEChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Head of RegulatoryMore ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXRepare TherapeuticsNASDAQ:RPTXFibroBiologicsNASDAQ:FBLGAdlai NortyeNASDAQ:ANLProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsidersMovers Lab Fund I Lp PrimeSold 25,089 sharesTotal: $41,898.63 ($1.67/share)Movers Lab Fund I Lp PrimeSold 5,308 sharesTotal: $9,979.04 ($1.88/share)View All Insider Transactions VAXX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxxinity stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VAXX shares. View VAXX analyst ratings or view top-rated stocks. What is Vaxxinity's stock price target for 2024? 1 equities research analysts have issued 12 month target prices for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 2,158.1% from the stock's current price. View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts. How have VAXX shares performed in 2024? Vaxxinity's stock was trading at $0.85 on January 1st, 2024. Since then, VAXX stock has decreased by 63.5% and is now trading at $0.31. View the best growth stocks for 2024 here. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) posted its quarterly earnings results on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an IPO on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VAXX) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
